Kristian Talvitie CFO Q3'25 FINANCIAL RESULTS Neil Barua CEO July 30, 2025 FORWARD LOOKING STATEMENTS This presentation includes forward looking statements regarding PTC's future financial performance, strategic outlook and expectations, anticipated future operations, expected effects of strategic investments and initiatives, and share repurchase expectations. Because such statements deal with future events, actual results may differ materially from those projected in the forward-looking statements. Informa ...

PTC ANNOUNCES THIRD FISCAL QUARTER 2025 RESULTS BOSTON, MA, July 30, 2025 - PTC (NASDAQ: PTC) today reported financial results for its third fiscal quarter ended June 30, 2025. "Q3 was another solid quarter of execution for PTC. Our strategy of enabling product data foundations and extending the value of that data across the enterprise is resonating with customers across our verticals and geographies," said Neil Barua, President and CEO, PTC. "In Q3, we continued to advance our go-to-market transformation, ...

BOSTON, July 30, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its third fiscal quarter ended June 30, 2025. "Q3 was another solid quarter of execution for PTC. Our strategy of enabling product data foundations and extending the value of that data across the enterprise is resonating with customers across our verticals and geographies," said Neil Barua, President and CEO, PTC. "In Q3, we continued to advance our go-to-market transformation, and I can say with confidence that we ...

Core Insights - PTC is expanding its collaboration with NVIDIA to integrate Omniverse technologies into its Creo and Windchill solutions, enhancing design, simulation, and collaboration for complex products [1][4] - The integration aims to improve product development processes by providing real-time, immersive simulation environments, allowing teams to visualize and interact with design data [3][4] - PTC has joined the Alliance for OpenUSD, emphasizing its commitment to open standards and interoperability in 3D data for AI infrastructure [1][7] Company Developments - The integration of NVIDIA Omniverse technologies into PTC's offerings will enable faster and more precise movement from concept to production for designers and manufacturers [5][7] - PTC's collaboration with NVIDIA builds on its history of supporting NVIDIA in delivering advanced hardware for AI, including high-performance PCBs and data center systems [4][5] - The integration is expected to serve as a model for extending capabilities to other AI hardware partners, enhancing joint innovation speed and quality [4][5] Industry Impact - The partnership addresses the increasing complexity of modern products, which require integrated and engineering-intensive design processes [4] - By leveraging real-time simulation and immersive visualization, companies can accelerate development cycles and improve product quality across the entire lifecycle [3][4] - PTC's commitment to OpenUSD and open standards is anticipated to unify the global AI infrastructure industry from design to manufacturing [5][7]

Core Viewpoint - The U.S. FDA has approved PTC Therapeutics' PTCT SEPHIENCE (sepiapterin) for treating phenylketonuria (PKU), a rare genetic disorder, which is expected to significantly impact the company's future revenue and position in the market [1][4][7]. Group 1: Product Approval and Market Potential - The approval includes broad labeling for hyperphenylalaninemia (HPA) in patients aged one month and older with sepiapterin-responsive PKU [2]. - The FDA's decision is based on significant efficacy and safety data from the Phase 3 APHENITY trial and its long-term extension study [4]. - PTC Therapeutics anticipates a potential revenue opportunity exceeding $1 billion for Sephience [6]. Group 2: Commercial Strategy - The initial commercial launch strategy will target 1,200 prescribers across 104 centers, covering over 80% of PKU claims data in the U.S. [4]. - The wholesale acquisition cost (WAC) for Sephience is approximately $40,000 per month or $480,000 per year [5]. - The company will prioritize patients who have not responded well to existing oral therapies, estimated to include 40% of the PKU population [5][6]. Group 3: Analyst Insights and Stock Performance - Analysts view the approval as a significant achievement for PTC, with expectations that Sephience could become the new standard of care for PKU patients [7]. - William Blair projects peak global sales for Sephience to reach $2.2 billion by 2031 and total revenue of $1.71 billion in 2025 [7]. - PTC stock has seen a price increase of 12.44%, reaching $49.86 at the time of publication [9].

PTC Therapeutics, Inc. PTCT announced it has gained FDA approval for SEPHIENCE on Monday. "We are excited to have reached this important milestone for those affected by PKU," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "The broad labeling reflects the potential of Sephience to meet the significant unmet need of PKU patients. The Sephience clinical data along with our expertise in launching rare disease therapies position Sephience to become the future standard of care. Our expe ...

Wall Street analysts expect PTC Inc. (PTC) to post quarterly earnings of $1.22 per share in its upcoming report, which indicates a year-over-year increase of 24.5%. Revenues are expected to be $582.4 million, up 12.3% from the year-ago quarter. The current level reflects an upward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Prior to a compa ...

Core Viewpoint - PTC Therapeutics, Inc. has received FDA approval for SEPHIENCE™ (sepiapterin) to treat phenylketonuria (PKU), marking a significant advancement for patients with this rare metabolic disorder [1][2][3] Group 1: FDA Approval and Product Details - SEPHIENCE is approved for treating hyperphenylalaninemia (HPA) in patients aged 1 month and older with sepiapterin-responsive PKU [1][6] - The approval is based on positive results from the Phase 3 APHENITY trial, demonstrating significant efficacy and safety [2][3] - SEPHIENCE acts as a natural precursor of the enzymatic co-factor BH4, effectively reducing blood phenylalanine levels [5] Group 2: Market Potential and Community Impact - The broad labeling of SEPHIENCE reflects its potential to address the unmet needs of PKU patients, with expectations to become the future standard of care [2] - The approval is seen as a milestone for the PKU community, providing renewed hope for improved quality of life for affected individuals [3] - SEPHIENCE has also received marketing authorization from the European Commission, with ongoing reviews in countries like Japan and Brazil [3] Group 3: Company Strategy and Future Plans - PTC Therapeutics is prepared to launch SEPHIENCE in the U.S. swiftly, leveraging its expertise in rare disease therapies [2] - The company plans to hold a conference call to discuss the approval and its implications for the market [4][9] - PTC aims to optimize value for patients through its diversified pipeline of transformative medicines for rare disorders [14]

Core Insights - PTC Inc. is set to report its third-quarter fiscal 2025 results on July 30, with anticipated revenues between $560 million and $600 million and non-GAAP EPS projected between $1.05 and $1.30 [1][8] - The Zacks Consensus Estimate for revenues stands at $582.4 million, reflecting a 12.3% increase year-over-year, while the earnings consensus is $1.22 per share, indicating a 24.5% rise from the previous year [1][2] Revenue and Earnings Performance - PTC has consistently exceeded the Zacks Consensus Estimate in the last four quarters, with an average earnings surprise of 15.4% [2] - Over the past year, PTC's shares have increased by 15.4%, compared to a 23% growth in the Zacks Computer – Software industry [2] Business Drivers - The core business segments, including product lifecycle management (PLM) and computer-aided design (CAD) solutions, are expected to be significant revenue contributors for the upcoming quarter [3] - Generative AI initiatives and enhancements to the product portfolio are anticipated to positively influence performance, with advancements across PLM, ALM, SLM, and CAD [4] Financial Expectations - For the fiscal third quarter, PTC expects cash from operations to be between $234 million and $239 million, and free cash flow to range from $230 million to $235 million, factoring in approximately $4 million in cash outflows related to restructuring efforts [5][8] - The company anticipates a sequential net annualized recurring revenues (ARR) growth of $30 million to $50 million for the fiscal third quarter [5] Market Challenges - PTC has narrowed its ARR outlook for fiscal 2025 to 7-9% from a previous estimate of 9-10%, citing global trade volatility and customer caution as contributing factors [6] - Adverse foreign currency exchange rates and intense competition in the CAD market are also expected to pose challenges [9] Recent Developments - PTC announced a partnership with Nimble to upgrade its design and operations systems to PTC's cloud-based solutions [10] - The introduction of the Arena Supply Chain Intelligence offering enhances PTC's PLM and QMS solutions with AI-driven component risk monitoring [11] - PTC launched model-based definition capabilities within its Onshape platform, marking a significant advancement in cloud-native CAD solutions [12] - The release of Creo 12, the latest version of PTC's CAD software, includes numerous enhancements aimed at improving design and collaboration [13]

Group 1 - Autodesk has reportedly backed off from a potential acquisition of PTC, focusing instead on organic investments and smaller acquisitions [2][3] - Following the speculation of the acquisition, Autodesk's stock initially fell, while PTC's stock experienced a significant rise, typical of merger arbitrage activities [2][3] - Despite the acquisition talks being off the table, PTC remains an attractive investment due to its consistent double-digit growth in software subscriptions and the increasing adoption of digital technologies [12][13] Group 2 - PTC is seen as a highly attractive asset in the context of ongoing consolidation in the industrial software sector, with notable acquisitions by companies like Siemens and Synopsys [5][6] - A potential combination of Autodesk and PTC would create a stronger competitor against European leaders in the CAD/PLM/CAE space, enhancing their market position [8][9] - PTC's solutions are integral to modern manufacturing, with expectations of continued growth in annual recurring revenue (ARR) and free cash flow, making it a solid option for diversified growth portfolios [12][13]